This document summarizes a drug study of Aripiprazole (Abilify) including its classification, indications, mechanism of action, dosage and administration, adverse reactions, and nursing considerations. Aripiprazole is an atypical antipsychotic used to treat schizophrenia, acute and maintenance of manic and mixed episodes associated with bipolar disorder, as well as adjunct treatment of major depressive disorder. It works as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and as an antagonist at 5-HT2A receptors. Common adverse reactions include CNS and neurological effects. Nurses should monitor for and report signs of neuroleptic malignant syndrome.
This document summarizes a drug study of Aripiprazole (Abilify) including its classification, indications, mechanism of action, dosage and administration, adverse reactions, and nursing considerations. Aripiprazole is an atypical antipsychotic used to treat schizophrenia, acute and maintenance of manic and mixed episodes associated with bipolar disorder, as well as adjunct treatment of major depressive disorder. It works as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and as an antagonist at 5-HT2A receptors. Common adverse reactions include CNS and neurological effects. Nurses should monitor for and report signs of neuroleptic malignant syndrome.
This document summarizes a drug study of Aripiprazole (Abilify) including its classification, indications, mechanism of action, dosage and administration, adverse reactions, and nursing considerations. Aripiprazole is an atypical antipsychotic used to treat schizophrenia, acute and maintenance of manic and mixed episodes associated with bipolar disorder, as well as adjunct treatment of major depressive disorder. It works as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and as an antagonist at 5-HT2A receptors. Common adverse reactions include CNS and neurological effects. Nurses should monitor for and report signs of neuroleptic malignant syndrome.
This document summarizes a drug study of Aripiprazole (Abilify) including its classification, indications, mechanism of action, dosage and administration, adverse reactions, and nursing considerations. Aripiprazole is an atypical antipsychotic used to treat schizophrenia, acute and maintenance of manic and mixed episodes associated with bipolar disorder, as well as adjunct treatment of major depressive disorder. It works as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and as an antagonist at 5-HT2A receptors. Common adverse reactions include CNS and neurological effects. Nurses should monitor for and report signs of neuroleptic malignant syndrome.
Download as DOCX, PDF, TXT or read online from Scribd
Download as docx, pdf, or txt
You are on page 1of 2
DRUG STUDY
Date Generic Brand Classificat Indication
Mechanism Dosage & Time Adverse Nursing Name Name ion of Action Frequency Given Reaction Consideration 05-08- Therapeut Schizophr Psychotrop ORAL CNS: · Monitor 21 Aripiprazol Abilify ic: enia. ic activity FORMUL akathisia, and report signs e antipsych Acute and may be ATIONS: confusion, of neuroleptic otics, maintena due to Aripipraz depression, malignant mood nce agonist ole IR: drowsiness syndrome, stabilizers therapy of activity at Monother , including manic and dopamine apy: extrapyrami hyperthermia, Pharmaco mixed D2 and -Initial dal diaphoresis, logic: episodes serotonin dose: 15 reactions, generalized dihydroca associate 5-HT1A mg orally fatigue, muscle rigidity, rbostyril d with receptors once a hostility, altered mental bipolar and day insomnia, status, disorder antagonist -Target lightheaded tachycardia, (as activity at dose: 15 ness, changes in monother the 5-HT2A mg orally manic blood pressure apy or receptor. once a reactions, (BP), and with Also has day; may impaired incontinence. lithium or alpha1- increase cognitive Symptoms valproate) adrenergic dose function, typically occur . Adjunct blocking based on nervousnes within 4–14 treatment activity. clinical s, days after of Therapeuti response. restlessnes initiation of depressio c Effects: Dose s, seizures, drug therapy, n in Decreased increases, suicidal but can occur at adults. manifestati if needed, thoughts, any time during Agitation ons of should be tardive drug use. associate schizophre at 2-week dyskinesia. d with nia; intervals to Resp: · Be alert for schizophr Decreased allow time dyspnea. new seizures or enia or mania in to achieve CV: increased bipolar bipolar steady bradycardia seizure activity, disorder. patients; state. , chest especially at Decreased -Maximum pain, the onset of symptoms dose: 30 edema, drug treatment. of mg/day hypertensio Document the depression. n, number, Decreased orthostatic duration, and agitation hypotensio severity of associated n, seizures, and with tachycardia report these schizophre . EENT: findings nia or blurred immediately to